European Healthtech Utilises AI for Obesity Care

Italian digital clinic Holifya has secured €2 million in investment to expand its AI-supported pharmacologic treatment for obesity. The company, described as the first digital clinic in Italy focusing on this area, leverages artificial intelligence and advanced diagnostics to provide care for obesity, including GLP-1 pharmacologic therapy. This funding round included €1.6 million in equity, according to a report by Tech.eu on September 1, 2026.

The investment underscores a growing trend in digital health and healthtech investment across Europe. Holifya's approach combines cutting-edge AI in healthcare with a digital clinic model, offering pharmacologic treatment for obesity. This innovative method aims to scale access to advanced diagnostics and personalised care, addressing a significant public health challenge. The focus on AI-supported care highlights the increasing integration of artificial intelligence into specialised medical fields, moving beyond traditional clinical settings.

The capital injection will support Holifya's efforts to scale its operations, particularly in the realm of AI-supported GLP-1 care. As a digital clinic, it represents a modern paradigm for delivering healthcare services, making specialised pharmacologic treatment more accessible. The strategic investment reflects confidence in the potential of AI and digital platforms to revolutionize obesity treatment and other complex health conditions. This development contributes to the broader landscape of European innovation in digital health, attracting significant healthtech investment.

What this means: This funding for Holifya demonstrates the continued flow of healthtech investment into AI-supported digital clinics, particularly those addressing chronic conditions like obesity in the European market. It signifies a growing reliance on artificial intelligence and advanced diagnostics to deliver scalable and specialised pharmacologic treatment.